Format

Send to

Choose Destination
Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):96-108. eCollection 2015.

Imaging of prostate cancer with PET/CT using (18)F-Fluorocholine.

Author information

1
Department of Radiology, Hospital for Sick Children, University of Toronto Toronto, Canada.
2
Department of Urology, St Vincent's Hospital Linz, Austria.
3
Department of Nuclear Medicine and Endocrinology, Paracelsus Private Medical University Salzburg, Austria.
4
PET - CT Center Linz, Department of Nuclear Medicine and Endocrinology, St Vincent's Hospital Linz, Austria.

Abstract

While (18)F-Fluorodeoxyglucose ((18)F-FDG) Positron-Emission Tomography (PET) has limited value in prostate cancer (PCa), it may be useful for specific subgroups of PCa patients with hormone-resistant poorly differentiated cell types. (18)F-Fluorocholine ((18)F-FCH) PET/CT has been increasingly used in primary and recurrent PCa and has been shown to add valuable information. Although there is a correlation between the foci of activity and the areas of malignancy in the prostate gland, the clinical value of (18)F-FCH is still controversial for detection of the malignant focus in the prostate. For the T-staging of PCa at diagnosis the value of (18)F-FCH is limited. This is probably due to limited resolution of PET system and positive findings in benign prostate diseases. Conversely, (18)F-FCH PET/CT is a promising imaging modality for the delineation of local and distant nodal recurrence and bone metastases and is poised to have an impact on therapy management. In this review, recent studies of (18)F-FCH PET/CT in PCa are summarized.

KEYWORDS:

18F-Fluorocholine; PET/CT; Prostate cancer

PMID:
25973332
PMCID:
PMC4396012

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center